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a b s t r a c t
Pontospinal noradrenergic neurons form part of an endogenous analgesic system that suppresses acute
pain, but there is conﬂicting evidence about its role in neuropathic pain. We investigated the chronology
of descending noradrenergic control during the development of a neuropathic pain phenotype in rats fol-
lowing tibial nerve transection (TNT). A lumbar intrathecal cannula was implanted at the time of nerve
injury allowing administration of selective a-adrenoceptor (a-AR) antagonists to sequentially assay their
effects upon the expression of allodynia and hyperalgesia. Following TNT animals progressively devel-
oped mechanical and cold allodynia (by day 10) and subsequently heat hypersensitivity (day 17). Block-
ade of a2-AR with intrathecal yohimbine (30 lg) revealed earlier ipsilateral sensitization of all modalities
while prazosin (30 lg, a1-AR) was without effect. Established allodynia (by day 21) was partly reversed
by the re-uptake inhibitor reboxetine (5 lg, i.t.) but yohimbine no longer had any sensitising effect. This
loss of effect coincided with a reduction in the descending noradrenergic innervation of the ipsilateral
lumbar dorsal horn. Yohimbine reversibly unmasked contralateral hindlimb allodynia and hyperalgesia
of all modalities and increased dorsal horn c-fos expression to an innocuous brush stimulus. Contralateral
thermal hyperalgesia was also reversibly uncovered by yohimbine administration in a contact heat ramp
paradigm in anaesthetised TNT rats. Following TNT there is an engagement of inhibitory a2-AR-mediated
noradrenergic tone which completely masks contralateral and transiently suppresses the development of
ipsilateral sensitization. This endogenous analgesic system plays a key role in shaping the spatial and
temporal expression of the neuropathic pain phenotype after nerve injury.
 2013 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
Neuropathic pain arises as a direct consequence of a lesion or
disease affecting the somatosensory system [55] and is associated
with considerable suffering, disability, and impaired quality of life.
An estimated 7–8% of the population suffer from neuropathic pain
[8,54] and the condition is poorly responsive to current treatments.
Monoamine re-uptake inhibitors (eg tricyclic antidepressants) are
one of the more commonly deployed treatments [2] with the most
beneﬁcial effects arising from Noradrenaline and (NA) reuptake
inhibition [3,48]. This is suggested to potentiate the actions of a
descending pain control system mediated by pontospinal NAergic
neurons which provide the sole source of NA in the spinal dorsal
horn [36,44].
These pontospinal projections release NA which acts via inhib-
itory a2-AR on both primary nociceptive afferents and second-or-
der projection neurons to suppress transmission of nociceptive
signals [44,66]. This descending NAergic system plays an impor-
tant role in acute pain processing [24,37,61,65] and in stress-in-
duced analgesia [7]. Using a targeted retrograde viral vector
approach we have shown the restraining effects these neurons
have on acute thermal and inﬂammatory nociception in vivo [21].
In contrast, the role of the NAergic system during neuropathic
pain has been more difﬁcult to mechanistically deﬁne. Several
models of neuropathic pain have associated plastic changes within
the NA system [4,16,50] and there is some evidence to suggest a
functional upregulation [31]. Such increased NA tone has been sug-
gested to suppress the expression of neuropathic phenotypes
accounting for the ‘‘failure rate’’ in the induction of allodynia and
hyperalgesia following nerve injury [12,62]. However, conﬂicting
evidence exists supporting a functional deﬁcit in the system
[45,58]. Once neuropathic pain is established, previous attempts
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to uncover a phenotype by blocking descending NAergic control
using viral vector-based approaches have been inconclusive [21]
as have lesion studies using selective NAergic toxins [22], suggest-
ing that there is little remaining NAergic tone in the system. This
proposed functional deﬁcit may account for the inability of the
endogenous analgesic system to correct the neuropathic pain phe-
notype and also explain the clinical and experimental therapeutic
beneﬁt from NA re-uptake inhibitors.
These contrasting strands of evidence have led us to examine
the chronology of descending NAergic control following nerve in-
jury while neuropathic pain behaviours are developing. Thus we
used sequential intrathecal NAergic antagonist/re-uptake inhibitor
administration to examine the longitudinal inﬂuence of the
descending pontospinal NA system on the expression of neuro-
pathic pain in the tibial nerve transection (TNT) variant of the
spared nerve injury (SNI) model [28].
2. Materials and methods
2.1. Animals
Experiments were performed on male Wistar rats (n = 59) (Har-
lan, UK). All procedures conformed to the UK animals (Scientiﬁc
Procedures) Act 1986. Animals were single housed, with an en-
riched environment under a standard 12 hours light/dark cycle,
with ad libitum access to food and water.
2.2. Surgery for tibial nerve transection and chronic intrathecal
cannulation
We used the tibial nerve transection (TNT) variant of the SNI
model [28]. Under ketamine (50 mg/kg) and medetomidine
(300 lg/kg) anaesthesia, the left hind limb was elevated and se-
cured in a lateral position and an incision was made at the mid-
thigh level longitudinally through the biceps femoris. The sciatic
nerve was exposed and the sural, tibial, and common peroneal
branches were identiﬁed. The tibial nerve was then tightly ligated
with 5-0 silk and a 2-mm section was cut, avoiding damage to sural
and common peroneal nerves (shown schematically in Fig. 1A).
Sham surgery consisted of the same procedure without tibial nerve
ligation/section.
While still anaesthetised a chronic intrathecal catheter was im-
planted at the L5–L6 interspace [51,57]. A sterilised 32-gauge
intrathecal catheter (CR3212; ReCathCo; Allison park; PA) was
threaded into a 25-gauge hypodermic needle which was inserted
between L5 and L6 vertebrae until a tail ﬂick indicated penetration
of the dura. The catheter was advanced cranially 2–3 cm so the ros-
tral tip reached the lumbar enlargement. The needle and catheter
stylet were removed and the catheter was joined to an 8 cm length
of PE-10 tubing which was sutured to the paraspinous muscle and
tunnelled subcutaneously to the level of the scapulae. The catheter
system was externalised by attaching the PE-10 tubing to a 2 cm
length of PE-50 tubing which was ﬁxed to a back mounted pedestal
system with a screw cap (313-000BM-10-SP with 6 mm side con-
nector; Plastics One, Roanoak, USA). Animals showing signs of poor
health or neurological dysfunction outside the nerve injury terri-
tory were excluded from the study (n = 3). Correct cannula place-
ment was indicated by immediate and reversible hindlimb
paralysis following a 20 lL intrathecal lidocaine injection (10 mg/
mL) on the day of surgery.
2.3. Nociceptive testing
Behavioural testing was carried out at baseline and at days 3, 5,
10, 12, 17, 19, 21, and 28 post surgery (Fig. 1B). The inﬂuence of
descending noradrenergic control over time was assayed following
single intrathecal doses (10 lL) at sequential time points of either
yohimbine (30 lg), prazosin (30 lg), reboxetine (5 lg), or saline.
On each study day nociceptive testing was carried out after dosing
with saline (control) and again 2 hours later after dosing with the
active drug (only 1 drug per day). The nociceptive tests were ap-
plied between 15 and 45 minutes after dosing. In time control
experiments the effects of drug had completely reversed by the fol-
lowing day (eg see Fig. 4D) and at least 48 hours were allowed to
lapse between successive doses.
2.4. Punctate mechanical allodynia
The hindpaw withdrawal thresholds to tactile stimuli were as-
sessed using calibrated von Frey ﬁlaments ranging from 0.17 to
26.0 g (TouchTest, Linton instruments, UK). Brieﬂy, rats were
placed in Perspex chambers with a metal mesh ﬂoor and were al-
lowed to habituate for 15 minutes before behavioural testing. Test-
ing started with the 2.0 g von Frey ﬁlament, applied perpendicular
to the plantar surface of the hindpaw for 3 seconds. Withdrawal
thresholds were analysed using the Dixon up/down statistical
method [10].
2.5. Cold allodynia
Hindpaw withdrawal responses to cooling stimuli were as-
sessed using the acetone test [11]. Following habituation, a 1-mL
syringe was used to apply a drop of acetone through the metal
mesh ﬂoor of the Perspex behavioural chambers to the plantar sur-
face of the hindpaw and a hindlimbwithdrawal was scored as a po-
sitive response. Acetone testing was repeated 5 times per pawwith
a 2-minute interval between tests and data are represented as a
percentage paw withdrawal frequency (PWF).
2.6. Thermal hyperalgesia
The plantar test was used to measure the hindpaw withdrawal
latency to heating stimuli [15]. Rats were placed in Perspex
chambers and allowed to habituate for 15 minutes. A radiant heat
source was focused onto the plantar surface of the hindpaw and
latency to withdrawal was recorded (Plantar test, Ugo Basile). A
30-second cut-off time was used to prevent tissue damage and
sensitisation.
2.7. Dynamic mechanical allodynia
In a further series of experiments the presence of contralateral
dynamic mechanical allodynia was sought by brushing the plantar
surface of the hindpaw with a thin camel hair brush (continuous
for 8 minutes) when animals were at days 19–21 post surgery.
Testing was performed on 4 groups of animals: TNT (n = 10) or
sham (n = 6) with half given yohimbine (30 lg, i.t.) and the remain-
der given vehicle. The animals were sacriﬁced 2 hours later for
trans-cardiac perfuse-ﬁxation with 4% formalin and the lumbar
spinal cord removed for c-fos immunohistochemistry (see below).
2.8. Contact heat ramp-evoked withdrawal
Contact heat ramp-evoked, hindpaw withdrawal experiments
were conducted on TNT animals with established allodynia and
hyperalgesia (at days 19–21 post surgery) and sham animals
(n = 20). Anaesthesia was induced using (1–2%) isoﬂurane in O2
until loss of paw withdrawal reﬂex and the external jugular vein
was cannulated for anaesthetic maintenance using continuous
intravenous infusion of alphaxalone (5 mg/mL, 9–15 mg/kg/h,
Alfaxan; Vetoquinol, UK) and the isoﬂurane was discontinued.
S.W. Hughes et al. / PAIN

154 (2013) 1680–1690 1681
Body temperature was maintained within physiological limits
(37.0C) using a feedback controlled heating blanket and rectal
probe.
The right carotid artery was cannulated for recording of blood
pressure and the trachea was cannulated to maintain a patent air-
way. A 32-gauge intrathecal catheter (CR3212; ReCathCo; Allison
Park; PA) was inserted through a 25-G needle at the L5–L6 inter-
space and fed rostrally to the lumbar enlargement to allow for drug
injection. Bipolar intramuscular electromyogram (EMG) electrodes
were inserted into either the ipsi- or contralateral biceps femoris
(stainless steel wire, 0.075 mm; Teﬂon coated, Advent Research
Materials, Eynsham, UK).
At the end of this preparatory surgery anaesthesia was light-
ened by decreasing the infusion rate of Alfaxan (10 mg/kg/h) to
a level at which animals were moderately responsive to brushing
of the cornea using a cotton swab. Animals were allowed to
stabilise at their new anaesthetic level for 60 minutes after surgical
preparation before recording EMG activity.
The EMG signal was ampliﬁed (5 k) and ﬁltered (50 Hz to
5 kHz; Neurolog; NL104 and NL125), before being captured for
analysis (10 kHz) via a 1401plus (Cambridge Electronic Design,
Cambridge, UK) onto a PC running Spike2 version 5 software (CED).
Controlled heat ramp stimuli were delivered to the dorsal sur-
face of the hindpaw using a custom-made contact heating lamp
assembly (as previously described [35]). The voltage applied to
the bulb was adjusted to deliver a heat ramp with a skin surface
heating rate of (7.5 ± 1C/s) monitored from a surface thermocou-
ple. Heat ramps were performed at 8-minute intervals to avoid
sensitisation of the hindpaw and a thermal cut off temperature
of 58C was used to prevent tissue damage. The threshold temper-
ature for onset of the EMG withdrawal response was measured for
each trial before and after drug dosing.
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Fig. 1. Pontospinal noradrenergic control transiently suppresses ipsilateral allodynia and hyperalgesia. (A) Schematic showing the surgical approach with ligation and tibial
nerve transection (TNT) immediately below the trifurcation of the sciatic nerve and insertion of the chronic intrathecal catheter at L5–6 that is exteriorised via an implanted
port for subsequent sequential intrathecal dosing. (B) Schedule of the sensory characterisation of the responses to ipsilateral mechanical, cold, and heat stimuli in TNT and
sham animals. For each animal the sensory proﬁle for the ipsilateral and contralateral hindlimbs was examined after vehicle (control) and two hours later after active drug
administration – either yohimbine (30 lg, i.t.), prazosin (30 lg, i.t.) or reboxetine (5 lg, i.t.). Mechanical allodynia (C) and cold allodynia (D) developed by day 10 in control
animals whereas after yohimbine administration allodynia was unmasked at an earlier stage (on day 3). In control animals, heat hyperalgesia was apparent on Hargreaves’
testing by day 17 (E) however yohimbine administration revealed latent heat hyperalgesia to be present at day 3 and day 10. Data are expressed as mean ± SEM, n = 6 in each
group. Comparisons between vehicle and yohimbine in TNT animals by two-way ANOVA with Bonferroni post tests; ⁄P < 0.01, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001. Comparisons against
baseline values, indicating time of onset of sensitisation following TNT, by one-way ANOVA with Dunnett’s multiple comparison test – signiﬁcance indicated with #P < 0.05,
##P < 0.01, and ###P < 0.001.
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2.9. Drugs
The drugs used in these experiments were yohimbine (a2-AR
antagonist, 30 lg in 10 lL of 20% DMSO; Tocris, UK), prazosin
(a1-AR antagonist, 30 lg in 10 lL of 30% DMSO; Tocris, UK;
[12,49,53], atipamezole (a2-AR antagonist, 50 lg in 10 lL saline;
Tocris, UK; [62]), clonidine (a2-AR agonist, 15 lg in 10 lL of saline,
Sigma, UK; [42]), and reboxetine (NA re-uptake inhibitor, 5 lg in
10 lL saline; Tocris, UK; [40]). All intrathecal drug injections were
made using a 50-lL Hamilton syringe at a rate of 0.5 lL/s fol-
lowed by a 17-lL dead space ﬂush with saline. Control experi-
ments with intrathecal administration of excipient were without
effect on any of the measures of nociception.
2.10. Immunohistochemistry
Rats were perfuse-ﬁxed with 4% formalin at days 19–21 post
surgery and the spinal cord was cryoprotected in 30% sucrose.
Transverse lumbar spinal cord sections (40 lm) were cut from
the lumbar enlargement into 3 series using a freezing microtome.
For immunocytochemistry they were washed (3) and permeabi-
lised with 0.1% Triton-X100 in 0.01M phosphate buffered
saline (PBS-T). Tissues from all groups were processed together
under identical conditions with the same reagents. Controls
were routinely run by omission of either primary or secondary
antibodies.
To reveal c-fos immunoreactivity the sections were incubated
free ﬂoating with a polyclonal rabbit c-fos antibody (SC-52, Santa
Cruz Biotechnology; 1:5000 in 0.1M phosphate buffer containing
1% bovine serum albumin, 1% normal goat serum, and 0.1% triton
X-100) for 24 hours at room temperature. After further washing
(3) this was followed by incubation with a biotinylated anti-rab-
bit IgG secondary antibody (Sigma; 1:500 in PBS-T) for 1–2 hours.
The sections were then incubated in extravidin peroxidase (Sigma;
1:1000 in PBS-T) for 1–2 hours and the peroxidase visualised using
3,3-diamino-benzidine (0.015%; Sigma) and glucose oxidase (after
[20,27]). The c-fos-labelled neuronal proﬁles were quantiﬁed by
manually counting in the superﬁcial laminae (I–II) of the dorsal
horn (identiﬁed under darkﬁeld illumination). The number of c-
fos-ir proﬁles were tallied from 3 non-contiguous spinal cord sec-
tions from each segment.
Dopamine-b-hydroxylase (DBH) immunohistochemistry was
performed on transverse sections (L4–L6) from TNT and sham
animals to a similar protocol using a mouse anti-DBH primary
antibody (1:5000, Millipore (Chemicon), MAB308) for 24 hours
followed by incubation with a biotinylated anti-mouse IgG (Sig-
ma; 1:500 in PBS-T) for 4 hours. The labelling was revealed using
the DAB glucose oxidase method as described above [27]. DBH
immunoreactivity was quantiﬁed for 3 non-contiguous spinal
cord sections selected at random from each segment (L4–L6).
The mounted sections were examined under brightﬁeld illumina-
tion at 20 magniﬁcation (Axioskop 2, Zeiss). Images of the dor-
sal horns were captured using a charge coupled device camera
(Axiocam 3, Zeiss) with the same exposure and illumination set-
ting for all sections. The images were analysed using ImageJ (NIH)
to identify the percentage of DBH positive pixels in the grey mat-
ter of the dorsal horn. The background level of staining was deter-
mined for each section (using ROI analysis of an area without
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Fig. 2. Prazosin has no effect on the development of sensitisation following tibial nerve transection (TNT) whereas reboxetine ameliorates established allodynia. Prazosin
administration (30 lg, i.t.) was without signiﬁcant effect on the development and expression of (A) mechanical allodynia or (B) cold allodynia at any time point. The selective
noradrenergic re-uptake inhibitor reboxetine (5 lg, i.t.) ameliorated the signs of established neuropathic sensitisation (3 weeks following nerve injury) and reduced both
mechanical (C) and cold allodynia (D). Data are expressed as mean ± SEM, n = 5 in each group. Comparisons between vehicle and active drug for TNT animals by two-way
ANOVA with Bonferroni post tests; ⁄P < 0.05. Comparisons against baseline values, indicating time of onset of sensitisation following TNT, by one-way ANOVA with Dunnett’s
multiple comparison test – signiﬁcance indicated with #P < 0.05, ##P < 0.01, and ###P < 0.001.
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visible DBH ﬁbres) and a value of 5 standard deviations above the
mean background level was used to set a threshold level for DBH
positive pixels. Each image was manually checked for accuracy
and to avoid inclusion of artefactual staining (particularly at the
margins of the tissue). The percentage of DBH-positive pixels
for ipsi- and contralateral dorsal horns was averaged from 6 sec-
tions per animal.
2.11. Statistical analysis
Data are presented as mean ± SEM. Differences across groups
were determined using either one- or two-way ANOVA or paired/
unpaired t-test as appropriate using GraphPad Prism software
(GraphPad Software Inc., USA). Levels of signiﬁcance were set as
⁄P < 0.05, ⁄⁄P < 0.01, and ⁄⁄⁄P < 0.001 (ns, not signiﬁcant).
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3. Results
The TNT animals progressively developed robust mechanical
and cold allodynia by day 10, with heat hyperalgesia developing la-
ter, by day 17 (Fig. 1C–E), which is in line with previous ﬁndings
using this model [19,28].
3.1. Descending noradrenergic tone transiently suppresses ipsilateral
neuropathic sensitisation
Administration of intrathecal yohimbine (30 lg) revealed hind-
limb sensitisation at an earlier time point of 3 days for mechanical
allodynia (control: 14.8 ± 2.5 g vs yohimbine: 5.7 ± 1.3 g, P < 0.001
Fig. 1C); cold allodynia (control: 28 ± 8% vs yohimbine: 72 ± 10%
paw withdrawals, P < 0.001 Fig. 1D) and heat hyperalgesia (con-
trol: 13.5 ± 0.8 s vs yohimbine: 9.5 ± 0.5 s, P < 0.05 Fig. 1E). Similar
effects were also seen with yohimbine at day 10 for heat
hyperalgesia.
In contrast intrathecal administration of prazosin (30 lg) had
no effect on the development of the neuropathic phenotype at
any time point (Fig. 2A,B). Yohimbine and prazosin were without
effect on mechanical or thermal sensitivity in sham animals.
Once hyperalgesia and allodynia were established yohimbine
was without effect on the mechanical and cold allodynia (day
17). However, this established mechanical and cold allodynia could
still be partially reversed by the NA re-uptake inhibitor reboxetine
(5 lg, i.t.) which increased paw withdrawal thresholds to
mechanical stimuli (P < 0.05 at day 21 Fig. 2C) and attenuated
paw withdrawals to cold stimulus (P < 0.05 at day 21 Fig. 2D).
Reboxetine had no effect on established heat hyperalgesia (data
not shown).
3.2. Tibial nerve transection decreases the descending noradrenergic
innervation of the ipsilateral lumbar dorsal horn
After TNT when the neuropathic sensitisation was established
(days 19–21) we found that the density of DBH-ir ﬁbres in the lum-
bar dorsal horn was signiﬁcantly lower on the ipsilateral side of
TNT animals compared to sham animals (P = 0.04, Fig. 3A, B, and
C, n = 3) whereas there was no signiﬁcant difference on the contra-
lateral side (Fig. 3D). This loss of ﬁbres appeared contained to the
ipsilateral lumbar dorsal horn which had signiﬁcantly lower den-
sity of DBH-ir at L4, L5, and L6 (Fig. 3E, P < 0.05, n = 3) than cervical
(C7) and thoracic (T12) segments. There was no signiﬁcant loss of
contralateral lumbar DBH-ir in TNT animals when comparing
across the segments or between sham animals, although in both
cases the absolute density of DBH-ir tended to be lower.
3.3. Descending noradrenergic tone completely masks contralateral
neuropathic sensitisation
TNT animals showed no sensitisation of their contralateral
hindlimb responses to nociceptive stimuli over the test period
(Fig. 4). However, contralateral mechanical allodynia was revealed
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was reversible over the course of an hour (for cold allodynia, n = 4). No residual sensitisation was evident after 90 minutes or on testing the following day. This sensitisation
was mimicked by administration of the a2-AR antagonist atipamezole (50 lg, i.t., n = 4) but not by prazosin (n = 3) or vehicle (n = 4). Data expressed as mean ± SEM.
Comparisons between vehicle and yohimbine for TNT animals (A, B, C) by two-way ANOVA with Bonferroni post tests. Comparisons against baseline values, indicating onset
of sensitisation, by one-way ANOVA with Dunnett’s multiple comparison test (D) (⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001).
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by intrathecal injection of yohimbine (30 lg, i.t.) in the same ani-
mals from day 3 following TNT (P < 0.05, n = 6, Fig. 4A) which be-
came more pronounced over time with the lowest thresholds
seen by day 17 (13.9 ± 2.2 g to 3.5 ± 1.1 g after yohimbine,
P < 0.01, Fig. 3A). Yohimbine also unmasked robust contralateral
cold allodynia with the proportion of acetone applications produc-
ing a paw withdrawal increasing from 8 ± 4% to 64 ± 8% (day 3,
P < 0.001 Fig. 4B) and contralateral heat hyperalgesia from day 3
(withdrawal latency 13.9 ± 1.0 s at baseline vs 10.4 ± 0.8 s,
P < 0.05, Fig. 4C). This yohimbine unmasking of sensitisation was
maximal between 15 and 45 minutes after administration and re-
versed over a time course of around an hour (cold allodynia
(Fig. 4D, n = 4) and dynamic brush allodynia (Fig. 5A, n = 3)). This
sensitising effect was mimicked by another a2-AR antagonist, atip-
amezole (50 lg, i.t.) which had a shorter duration of action (Fig. 4D,
n = 4). There was no sign of residual sensitisation on testing the fol-
lowing day (Fig. 4D). Prazosin (30 lg, i.t.) did not change the con-
tralateral responses to nociceptive testing at any time point in TNT
animals (see Fig. 4D, n = 3) nor did the vehicle control (data not
shown, n = 4). Yohimbine had no sensitising effect in naïve or sham
operated animals.
3.4. Spinal a2-AR antagonism unmasks contralateral dynamic
mechanical allodynia associated with increased dorsal horn c-fos
expression
Previous studies using the spared nerve injury model have
shown innocuous brush stimulation of the ipsilateral hindpaw to
trigger withdrawals and evoke increased c-fos expression in the
superﬁcial dorsal horn - indicating the presence of dynamic allo-
dynia [6]. Having noted the presence of contralateral dynamic
mechanical allodynia after yohimbine administration in the TNT
model (Fig. 5A). We followed a similar protocol to Bester et al.
[6] and after a period of repeated brush stimulation (8 minutes)
of the contralateral hindpaw we found a 6-fold increase
(P = 0.004, n = 5, Fig. 5B) in c-fos-labelled proﬁles in the superﬁcial
laminae of the L5 dorsal horn in the intrathecal yohimbine group.
In sham animals yohimbine administration did not cause an in-
crease in L5 c-fos expression to brush stimulus (6±2 vs 7±3),
n = 3/group). There was a similar level of L5 c-fos expression in
the sham groups to that seen in the TNT without yohimbine group.
3.5. Contralateral hypersensitivity to a ramped thermal stimulus is
unmasked by spinal a2-AR antagonism
We further tested the inﬂuence of the descending noradrenergic
system on thermal sensitivity by looking at changes in EMG with-
drawal thresholds to a controlled ramped heating stimulus applied
to the dorsum of the hindpaw in anaesthetised animals (at days
19–21 post TNT). The TNT animals showed ipsilateral heat sensiti-
sation with lower withdrawal thresholds (47.9 ± 1.0C TNT vs
52.7 ± 0.2C in sham, P < 0.05 Fig. 6A). Following intrathecal
yohimbine there was no change in the ipsilateral withdrawal
threshold in either group. However this sensitisation could be re-
versed by intrathecal clonidine (15 lg, n = 3, Fig. 6B) indicating
that a2-AR receptor function was preserved within these spinal
nociceptive circuits.
Contralateral withdrawal thresholds in TNT animals were not
sensitised; however yohimbine administration produced a repeat-
able and reversible sensitisation to the heat ramp stimulus, with a
peak change from baseline (54.6 ± 0.8C vs 47.4 ± 0.6C, P < 0.001,
Fig. 6C). The time course of this sensitising effect of yohimbine
peaked at around 40 minutes and reversed after approximately 1
hour (Fig. 6D).
4. Discussion
We investigated the chronology of inﬂuence of the descending
NAergic system on the development of the neuropathic pain phe-
notype following tibial nerve injury. Using a subtractive, longitudi-
nal, intrathecal antagonist approach we have shown that
descending NAergic tone delays the appearance of ipsilateral
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mechanical allodynia, cold allodynia, and heat hyperalgesia follow-
ing nerve injury via an a2-AR mediated mechanism. Once neuro-
pathic sensitisation was established there was no longer any
demonstrable effect of a2-AR antagonism, suggesting a diminution
of the inﬂuence of NAergic tone which was echoed anatomically by
a diminished density of DBH-ir-positive ﬁbres in the ipsilateral
dorsal horn. An unexpected and notable consequence of intrathecal
a2-AR blockade was the reversible unmasking of pronounced con-
tralateral neuropathic sensitisation to both thermal and mechani-
cal stimulation. These ﬁndings indicate that the descending
NAergic system acts dynamically to spatially restrict and tempo-
rally delay the expression of neuropathic pain at the spinal level.
They may also provide insight into the variability of expression
of neuropathic sensitisation across animal models and also be-
tween patients.
The role of the descending NAergic system in neuropathic pain
has attracted considerable attention asNAergic re-uptake inhibitors
have been found to be amongst themost effective treatments [2,48].
However, previous investigations have yielded conﬂicting evidence
regarding the functional role of the system in neuropathic pain. The
role of NAergic control has typically been investigated once the neu-
ropathic phenotype is established [21,22,31,45,46,58,62,63]. At this
point subtractive interventions such as pharmacological blockade
[21], genetic inhibition or toxin-mediated ablation [17,21,23] of
the descending NAergic pathway have generally shown minimal
or no effect upon sensitisation. Similarly at a cellular level there
was no change in response properties of dorsal horn neurons follow-
ing intrathecal delivery of NAergic antagonists [45]. This led Jasmin
et al. [23] to query the hypothesis that tricyclic antidepressants are
acting via a NAergic mechanism; however, an alternative explana-
tion is that these subtractive experiments (unlike interventions to
facilitate) will only have the power to reveal a phenotype if there
is a substantial basal level of tone in the NAergic system in neuro-
pathic pain.
Here we show that the descending NAergic system acts to delay
the appearance of neuropathic symptoms in the acute phase after
nerve injury. The development of the neuropathic phenotype in
the TNTmodel is slower (often taking over a week tomanifest) than
other nerve injury models (such as SNI [12]), which may reﬂect an
increased recruitment of endogenous analgesic systems in the early
stages after TNT. This NAergic inﬂuence diminishes to become
undetectable using pharmacological antagonists by day 10 – per-
haps because of a ﬂoor effect where further sensitisation is no long-
er discernible or possibly reﬂecting a functional diminution in the
tonic action of NAergic inhibition. This latter possibility is rein-
forced by a decrease in the density of the NAergic innervation of
the lumbar dorsal horn. However, there is still a low level of ongo-
ing NAergic inﬂuence even in established neuropathic sensitisation
as the reuptake blocker reboxetine can partially reverse the sensiti-
sation as has been shown previously for othermonoamine reuptake
inhibitors [25,32,39–41]. Additionally we demonstrate that the a2-
AR function in the spinal nociceptive circuits is still intact after TNT
as the sensitisation could be reversed with intrathecal clonidine –
in agreement with previous studies [63,67]. These ﬁndings indicate
that it is reduced pontospinal NAergic control ipsilaterally that is
unable to prevent the expression of sensitisation.
There is a recognised variability in the expression of neuro-
pathic signs following apparently similar surgical injuries in pain
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models that reﬂects species, strain, and environmental inﬂuences
[38]. It has been proposed that one signiﬁcant factor may be differ-
ences in the ability to recruit endogenous analgesic circuits [12,62].
For example, a subset of animals that failed to exhibit neuropathic
signs after spinal nerve ligation (SNL) showed clear evidence of
allodynia after intrathecal a2-AR blockade suggesting that the
NAergic system was acting to oppose sensitisation in this resistant
group [62]. A similar observation has recently been made with Hol-
tzman rats that failed to develop allodynia after SNL, where again
sensitisation was revealed by spinal a2-receptor blockade [12].
This variation may mirror clinical experience where only a minor-
ity of patients with apparently similar nerve injuries will go on to
develop neuropathic pain [5] and it has been shown that the risk of
developing chronic pain after surgery are inﬂuenced by the ability
to recruit endogenous analgesic systems [64].
There have been reports of upregulation of the NAergic innerva-
tion of the spinal cord in nerve injury models, that is chronic con-
striction injury (CCI) [31] and SNL [16] unlike the segmentally
restricted downregulation that we have found here to be associ-
ated with functional loss of descending NAergic tone in the TNT
model. This may indicate that different NAergic neuroplastic
mechanisms are at work in these models of neuropathic pain.
Our demonstration of a segmentally localised loss of NAergic
innervation (assessed with DBH immunohistochemistry) with
sparing of thoracic and cervical segments is consistent with our
previous observation of a segmental topography to the LC innerva-
tion of the spinal cord [21]. At this point we are unable to discrim-
inate between speciﬁc loss of local NAergic ﬁbres or degenerative
loss of NAergic neuronal somata or diminished DBH content in
the ﬁbres. We note that identiﬁcation of the underlying mecha-
nism(s) for this NAergic downregulation/retraction may provide a
therapeutic target to quell sensitisation in neuropathic pain states.
Blockade of descending NAergic inhibition with intrathecal
yohimbine unmasked, from the earliest stages, latent neuropathic
sensitisation to all modalities in the contralateral hindlimb of rats
with TNT. This yohimbine-induced, transient, contralateral sensiti-
sation was also demonstrated in a contact heat ramp assay – an as-
say that is known to be subject to modulation by descending
control [18,34]. Similarly, brushing of the contralateral hindpaw
after yohimbine triggered paw withdrawals and a markedly in-
creased level of dorsal horn c-fos expression consistent with the
presence of dynamic mechanical allodynia. None of the TNT ani-
mals exhibited signiﬁcant sensitisation of the contralateral hind-
limb without yohimbine blockade, and yohimbine was without
effect in sham animals. These ﬁndings indicate that the descending
NAergic system is dynamically and actively recruited to oppose the
expression of neuropathic pain and acts to spatially restrict the
sensitised territory via an a2-mediated inhibition.
Contralateral neuropathic sensitisation has been reported to oc-
cur in some but not all animal models of neuropathic pain includ-
ing CCI [43], SNL [1] and partial spinal nerve ligation (PSNL) [67].
Variation in the development of contralateral hypersensitivity
has also been reported in the SNI model [13,14]. It has been pro-
posed that such mirror-image sensitisation may be subject to reg-
ulation by endogenous analgesic mechanisms [59], and this
suppression can be mimicked by the systemic administration of
the a2-agonist clonidine [67]. We have extended these ﬁndings
to show that mirror-image sensitisation can be uncovered by
blocking descending NAergic tone indicating that these pontospi-
nal neurons are actively opposing the spread of sensitisation at a
spinal level. The engagement of such a mechanism to spatially re-
strict the spread of sensitisation may account for our previous
observations of homotopic stimulation-evoked shrinkage of an
area of allodynia in patients with neuropathic pain [30].
Clinically, extraterritorial spread of pain following a unilateral
nerve injury (ie complex regional pain syndrome (CRPS) type II)
is a recognised [56] but confusing and challenging feature of
chronic pain states. In particular, mirror pains have long been
recognised [29] but within neurological diagnostic sieves where
the importance of symptom laterality is emphasised this can be
interpreted as indicating ‘‘supra-tentorial’’ psychological factors
or the development of a ‘‘functional’’ pain state. The reasons for
the bilateral spread of neuropathic symptoms are still unclear
but are thought to be partly due to maladaptive neuronal plasticity
and/or glial activation at a spinal level [26,60]. Additionally, there
is some evidence to suggest supraspinal changes [33,52] in CRPS as
well as changes in the activity of the patients own endogenous
analgesic systems [47]. A key question is why the majority of pa-
tients with a unilateral injury do not develop an extraterritorial
spread of symptoms – we posit that this may well relate to the
ability to recruit descending NAergic control systems that spatially
restrict the spread of sensitisation. As such this pontospinal NAer-
gic mechanism provides a potential link between the aforemen-
tioned ‘‘supra-tentorial’’ factors and the spinal spread of
neuropathic sensitisation.
In summary, the study presented here demonstrates the tem-
poral proﬁle of the endogenous analgesic action of pontospinal
noradrenergic neurons during the development of neuropathic
sensitisation following a unilateral nerve injury. We have shown
that the system transiently inhibits ipsilateral and completely
masks contralateral sensitisation; together this indicates that
pontospinal NAergic neurons play an important role in shaping
the expression of the neuropathic phenotype. We suggest that
differences in the susceptibility to developing both ipsilateral
and contralateral neuropathic pain seen with nerve injuries
across animal models and indeed between individual patients
may be in part due to variation in the engagement of the endog-
enous NAergic analgesic system. Further it may provide a ratio-
nale for the early use of NA re-uptake inhibitors in patients
with neuropathic pain to delay, ameliorate, and spatially restrict
the spread of neuropathic sensitisation – as has been reported to
be effective in preventing progression of shingles to post-herpetic
neuralgia [9].
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